AB0682 EXPRESSION AND SIGNIFICANCE ANALYSIS OF PEROXIREDOXIN 6 IN RHEUMATOID ARTHRITIS PATIENTS

Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pat...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 83; no. Suppl 1; p. 1628
Main Authors Guo, H., Zheng, X., Wang, R., Zheng, Y., Zhang, W., Zhong, X., Long, L.
Format Journal Article
LanguageEnglish
Published Kidlington BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2024
Elsevier B.V
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pathogenesis of RA. Peroxiredoxin 6(Prdx6), a newly discovered member of the peroxidase family, has both glutathione-peroxidase activity and phospholipase A2 activity, and plays an important role in anti-oxidative stress damage and apoptosis regulation. Current researchs on Prdx6 to attenuate oxidative damage has focused on the respiratory, nervous, and digestive systems, with fewer studies on rheumatic and immune systems.Objectives:The purpose of this study was to investigate the expression of Prdx6 in serum of patients with RA and its correlation with disease activity,inflammatory indicators.Methods:57 patients diagnosed with RA and 31 demographically matched healthy control subjects participated in this study.Clinical datas of enrolled RA patients were collected,including disease activity, inflammatory markers, cytokines, and immune markers. Disease activity indices of patients were calculated with Disease Activity Score-28 Index(DAS-28). The levels of Prdx6 in serum samples were measured by Enzyme-Linked Immunosorbent Assay(ELISA). RA patients were categorized into two groups according to disease activity: low-moderate disease activity and high disease activity. The results obtained were analyzed by multivariate statistical analysis.Results:The serum Prdx6 level of RA patients was significantly decreased compared with that of healthy control group(1.307±0.500ng/ml vs 2.051±0.775ng/ml, p<0.05). Additionally,erythrocyte sedimentation rate(ESR) was faster in the group with high disease activity than the group with low-moderate disease activity(p<0.05). However,there were no statistically significant differences in immunoglobulin,complement,rheumatoid factor(RF),C-reactive proteinand(CRP),anti-cyclic citrullinated peptide(CCP) antibodies between patients with different levels of disease activity. Meanwhile,disease activity and ESR were negatively correlated with prdx6 level(rs -0.284,p<0.05;rs -0.332,p<0.05). But there was no correlation between prdx6 levels and CRP, IL-6, TNF-ɑ, immunoglobulin, RF,anti-CCP antibodies.Conclusion:Our study shows that prdx6 expression is decreased in RA patients and it was negatively correlated with disease activity and ESR,but its specific pathway of action is unclear and needs further study. Exogenous supplement of Prdx6 may alleviate the oxidative stress damage in RA patients and may be one of the treatment methods for RA.REFERENCES:[1] Wu H, Wu R, Liu T, et al. Peroxiredoxin 6 alleviates high glucose-induced inflammation and apoptosis in HK-2 cells by inhibiting TLR4/NF-κB signaling[J]. Ann Transl Med. 2023;11(2):41.[2] Chen X, Tzekov R, Su M, et al. Hydrogen peroxide-induced oxidative damage and protective role of peroxiredoxin 6 protein via EGFR/ERK signaling pathway in RPE cells[J]. Front Aging Neurosci. 2023;15:1169211.[3] Quiñonez-Flores CM, González-Chávez SA, Del Río Nájera D,et al. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. Biomed Res Int. 2016;2016:6097417.[4] Zamudio-Cuevas Y, Martínez-Flores K, Martínez-Nava GA,et al. Rheumatoid Arthritis and Oxidative Stress[J]. Cell Mol Biol (Noisy-le-grand). 2022;68(6):174-184.Acknowledgements:NIL.Disclosure of Interests:None declared.
AbstractList Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pathogenesis of RA. Peroxiredoxin 6(Prdx6), a newly discovered member of the peroxidase family, has both glutathione-peroxidase activity and phospholipase A2 activity, and plays an important role in anti-oxidative stress damage and apoptosis regulation. Current researchs on Prdx6 to attenuate oxidative damage has focused on the respiratory, nervous, and digestive systems, with fewer studies on rheumatic and immune systems.Objectives:The purpose of this study was to investigate the expression of Prdx6 in serum of patients with RA and its correlation with disease activity,inflammatory indicators.Methods:57 patients diagnosed with RA and 31 demographically matched healthy control subjects participated in this study.Clinical datas of enrolled RA patients were collected,including disease activity, inflammatory markers, cytokines, and immune markers. Disease activity indices of patients were calculated with Disease Activity Score-28 Index(DAS-28). The levels of Prdx6 in serum samples were measured by Enzyme-Linked Immunosorbent Assay(ELISA). RA patients were categorized into two groups according to disease activity: low-moderate disease activity and high disease activity. The results obtained were analyzed by multivariate statistical analysis.Results:The serum Prdx6 level of RA patients was significantly decreased compared with that of healthy control group(1.307±0.500ng/ml vs 2.051±0.775ng/ml, p<0.05). Additionally,erythrocyte sedimentation rate(ESR) was faster in the group with high disease activity than the group with low-moderate disease activity(p<0.05). However,there were no statistically significant differences in immunoglobulin,complement,rheumatoid factor(RF),C-reactive proteinand(CRP),anti-cyclic citrullinated peptide(CCP) antibodies between patients with different levels of disease activity. Meanwhile,disease activity and ESR were negatively correlated with prdx6 level(rs -0.284,p<0.05;rs -0.332,p<0.05). But there was no correlation between prdx6 levels and CRP, IL-6, TNF-ɑ, immunoglobulin, RF,anti-CCP antibodies.Conclusion:Our study shows that prdx6 expression is decreased in RA patients and it was negatively correlated with disease activity and ESR,but its specific pathway of action is unclear and needs further study. Exogenous supplement of Prdx6 may alleviate the oxidative stress damage in RA patients and may be one of the treatment methods for RA.REFERENCES:[1] Wu H, Wu R, Liu T, et al. Peroxiredoxin 6 alleviates high glucose-induced inflammation and apoptosis in HK-2 cells by inhibiting TLR4/NF-κB signaling[J]. Ann Transl Med. 2023;11(2):41.[2] Chen X, Tzekov R, Su M, et al. Hydrogen peroxide-induced oxidative damage and protective role of peroxiredoxin 6 protein via EGFR/ERK signaling pathway in RPE cells[J]. Front Aging Neurosci. 2023;15:1169211.[3] Quiñonez-Flores CM, González-Chávez SA, Del Río Nájera D,et al. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. Biomed Res Int. 2016;2016:6097417.[4] Zamudio-Cuevas Y, Martínez-Flores K, Martínez-Nava GA,et al. Rheumatoid Arthritis and Oxidative Stress[J]. Cell Mol Biol (Noisy-le-grand). 2022;68(6):174-184.Acknowledgements:NIL.Disclosure of Interests:None declared.
Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the pathophysiological of RA mechanism is not yet fully documented,previous studies have shown that oxidative stress is an important part of the pathogenesis of RA. Peroxiredoxin 6(Prdx6), a newly discovered member of the peroxidase family, has both glutathione-peroxidase activity and phospholipase A2 activity, and plays an important role in anti-oxidative stress damage and apoptosis regulation. Current researchs on Prdx6 to attenuate oxidative damage has focused on the respiratory, nervous, and digestive systems, with fewer studies on rheumatic and immune systems. The purpose of this study was to investigate the expression of Prdx6 in serum of patients with RA and its correlation with disease activity,inflammatory indicators. 57 patients diagnosed with RA and 31 demographically matched healthy control subjects participated in this study.Clinical datas of enrolled RA patients were collected,including disease activity, inflammatory markers, cytokines, and immune markers. Disease activity indices of patients were calculated with Disease Activity Score-28 Index(DAS-28). The levels of Prdx6 in serum samples were measured by Enzyme-Linked Immunosorbent Assay(ELISA). RA patients were categorized into two groups according to disease activity: low-moderate disease activity and high disease activity. The results obtained were analyzed by multivariate statistical analysis. The serum Prdx6 level of RA patients was significantly decreased compared with that of healthy control group(1.307±0.500ng/ml vs 2.051±0.775ng/ml, p<0.05). Additionally,erythrocyte sedimentation rate(ESR) was faster in the group with high disease activity than the group with low-moderate disease activity(p<0.05). However,there were no statistically significant differences in immunoglobulin,complement,rheumatoid factor(RF),C-reactive proteinand(CRP),anti-cyclic citrullinated peptide(CCP) antibodies between patients with different levels of disease activity. Meanwhile,disease activity and ESR were negatively correlated with prdx6 level(rs -0.284,p<0.05;rs -0.332,p<0.05). But there was no correlation between prdx6 levels and CRP, IL-6, TNF-ɑ, immunoglobulin, RF,anti-CCP antibodies. Our study shows that prdx6 expression is decreased in RA patients and it was negatively correlated with disease activity and ESR,but its specific pathway of action is unclear and needs further study. Exogenous supplement of Prdx6 may alleviate the oxidative stress damage in RA patients and may be one of the treatment methods for RA. [1] Wu H, Wu R, Liu T, et al. Peroxiredoxin 6 alleviates high glucose-induced inflammation and apoptosis in HK-2 cells by inhibiting TLR4/NF-κB signaling[J]. Ann Transl Med. 2023;11(2):41. [2] Chen X, Tzekov R, Su M, et al. Hydrogen peroxide-induced oxidative damage and protective role of peroxiredoxin 6 protein via EGFR/ERK signaling pathway in RPE cells[J]. Front Aging Neurosci. 2023;15:1169211. [3] Quiñonez-Flores CM, González-Chávez SA, Del Río Nájera D,et al. Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. Biomed Res Int. 2016;2016:6097417. [4] Zamudio-Cuevas Y, Martínez-Flores K, Martínez-Nava GA,et al. Rheumatoid Arthritis and Oxidative Stress[J]. Cell Mol Biol (Noisy-le-grand). 2022;68(6):174-184. NIL. None declared.
Author Long, L.
Wang, R.
Zhong, X.
Guo, H.
Zheng, X.
Zheng, Y.
Zhang, W.
Author_xml – sequence: 1
  givenname: H.
  surname: Guo
  fullname: Guo, H.
  organization: University of Electronic Science and Technology of China, Chengdu, China
– sequence: 2
  givenname: X.
  surname: Zheng
  fullname: Zheng, X.
  organization: Sichuan Provincial People’s Hospital, Chengdu, China
– sequence: 3
  givenname: R.
  surname: Wang
  fullname: Wang, R.
  organization: Sichuan Provincial People’s Hospital, Chengdu, China
– sequence: 4
  givenname: Y.
  surname: Zheng
  fullname: Zheng, Y.
  organization: Sichuan Provincial People’s Hospital, Chengdu, China
– sequence: 5
  givenname: W.
  surname: Zhang
  fullname: Zhang, W.
  organization: Sichuan Provincial People’s Hospital, Chengdu, China
– sequence: 6
  givenname: X.
  surname: Zhong
  fullname: Zhong, X.
  organization: Chongqing General Hospital, Department of Geratology, Chongqing, China
– sequence: 7
  givenname: L.
  surname: Long
  fullname: Long, L.
  organization: Sichuan Provincial People’s Hospital, Department of Rheumatology, Chengdu, China
BookMark eNqNkN9OgzAUxhujifPPO5B4jbbQlhKvcOu2JhMWYMm8aqCUyOJAy2binTe-qE9iJyZ66c1pe_J93-n5nYHjtms1AFcIXiPk05uibc2j3m-rpnc96GFX758Kc-15AT4CI4Qps20Kj8EIQui7OKTBKTjr-419QobYCBTRHaTM-3z_4OtlyrNMJLETxRMnE7NYTMU4isfcNqLFQyYyJ5k6S54ma5Hyia2xQx1b0jlf3Ud5IiZOlObzVORWuoxyweM8uwAndfHU68uf8xyspjwfz91FMrPxC7dEIWRuTSpCFApCRTStIKU4RKr2y7IOUIVCQnSlSVFjVbNQF5jVqLArKOXjsrJ37J-DqyH32XQve93v5Kbbm9aOlD6khFESesyqbgeVMl3fG13LZ9NsC_MmEZQHpvIPU3lgKr-ZygNT6-aDW9tFXhttZK8a3SpdNUarnay65p85wZBTbje_3_yP8wvaEpaW
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc.
2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Copyright_xml – notice: Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: 2024 © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc.
– notice: 2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
DBID AAYXX
CITATION
K9.
DOI 10.1136/annrheumdis-2024-eular.2274
DatabaseName CrossRef
ProQuest Health & Medical Complete (Alumni)
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
DatabaseTitleList
ProQuest Health & Medical Complete (Alumni)

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 1628
ExternalDocumentID 10_1136_annrheumdis_2024_eular_2274
S000349672417358X
annrheumdis
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
0R~
AAFWJ
AALRI
PHGZM
PJZUB
PPXIY
PQGLB
PUEGO
AAYXX
CITATION
K9.
ID FETCH-LOGICAL-b1908-f5d55c179c5e6d066491cf3bbf71d1955ede5af4cf89ea48f1a008cc34bdf1a43
ISSN 0003-4967
IngestDate Fri Jul 25 11:09:14 EDT 2025
Thu Jul 31 00:26:26 EDT 2025
Sat Aug 30 17:13:07 EDT 2025
Thu Apr 24 22:50:08 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue Suppl 1
Keywords Biomarkers
Cytokines and Chemokines
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b1908-f5d55c179c5e6d066491cf3bbf71d1955ede5af4cf89ea48f1a008cc34bdf1a43
Notes EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
PQID 3065865928
PQPubID 2041045
PageCount 1
ParticipantIDs proquest_journals_3065865928
crossref_primary_10_1136_annrheumdis_2024_eular_2274
elsevier_sciencedirect_doi_10_1136_annrheumdis_2024_eular_2274
bmj_journals_10_1136_annrheumdis_2024_eular_2274
PublicationCentury 2000
PublicationDate 2024-June
June 2024
2024-06-00
20240601
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: 2024-June
PublicationDecade 2020
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAbbrev Ann Rheum Dis
PublicationYear 2024
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
Elsevier B.V
Elsevier Limited
Publisher_xml – name: BMJ Publishing Group Ltd and European League Against Rheumatism
– name: Elsevier B.V
– name: Elsevier Limited
SSID ssj0000818
Score 2.4464602
Snippet Background:Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the...
Rheumatoid arthritis(RA) is a systemic autoimmune disease,which causes joint inflammation, cartilage degeneration and bone erosion. Although the...
SourceID proquest
crossref
elsevier
bmj
SourceType Aggregation Database
Index Database
Publisher
StartPage 1628
SubjectTerms Apoptosis
Autoimmune diseases
Biomarkers
Citrulline
Cytokines and Chemokines
Enzyme-linked immunosorbent assay
Erythrocyte sedimentation rate
Glutathione
Hydrogen peroxide
Immunoglobulins
NF-κB protein
Oxidative stress
Pathogenesis
Patients
Peroxiredoxin
Phospholipase A2
Rheumatoid arthritis
Rheumatoid factor
Scientific Abstracts
Signal transduction
Statistical analysis
TLR4 protein
Toll-like receptors
Title AB0682 EXPRESSION AND SIGNIFICANCE ANALYSIS OF PEROXIREDOXIN 6 IN RHEUMATOID ARTHRITIS PATIENTS
URI https://ard.bmj.com/content/83/Suppl_1/1628.1.full
https://dx.doi.org/10.1136/annrheumdis-2024-eular.2274
https://www.proquest.com/docview/3065865928
Volume 83
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgkyZeEFcxGJMleKtSkthOnRekbEuXIJpWaSqypyh2HCEkCoL2hV_PsXPrNkBlL1ZkpaenPp_tz-65IPSWV5UA1sGsuqbMory2LaARxLIVp4KUrqw8He88S7xoRT_kLB9cgkx0yUaM5a8_xpXcxarQB3bVUbL_YdleKHTAM9gXWrAwtHvZODizPe6OwtyMoy6fo5NFLePLJJ7qUo7nIXQEH6-WsalQvgjTeR6n4QW0ycgbQZNG4WoWZPP4YgTMNkrjDF5dBFkcJtlyl7gOiZaNT-JntW1yvbZ_8PTM_HJr7l6j8XAjrZrlJO-7PrV31Ontl67Gu9cQLh3cpfqllVjUb2prdEsrJztro-M1YeC3F23SZis2yoPelvkCpf1wx67bVPG5nir7xhbWOxaaIw0xYdadsEILK4ywQgu7jw5dOFLoaheTfDLs2tzhXXVF_TOO0JtWt3f_0AwYifj65W-c5sbubihL9gg9bM8aOGiA8xjdU-sn6GjWelM8RUWDHzzgBwN-8C5-cIcfPJ_ia_jBHoZmwA_u8YM7_DxDq2mYnUdWW3DDEsALuVWzijEJS7RkyquAjFLfkTURop44leMzpirFyprKmvuqhIntlDBuUhIqKnim5Dk6WH9bqxcI20xQoQOzS5cA5SnhIOdLRYUnSWlXLjlGNgxc0U6mn8UehjtGtBvl4nuTimW_j73vLFK0rLJhiwXgbz8BJ50dB32Jpu7aJYG_vJtar9CDYRqdoIPNj616Dfx2I04NME_R4VmYLNLf0BmZvA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AB0682+EXPRESSION+AND+SIGNIFICANCE+ANALYSIS+OF+PEROXIREDOXIN+6+IN+RHEUMATOID+ARTHRITIS+PATIENTS&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Guo%2C+H.&rft.au=Zheng%2C+X.&rft.au=Wang%2C+R.&rft.au=Zheng%2C+Y.&rft.date=2024-06-01&rft.issn=0003-4967&rft.volume=83&rft.spage=1628&rft_id=info:doi/10.1136%2Fannrheumdis-2024-eular.2274&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_annrheumdis_2024_eular_2274
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon